The result suggested the potentials of HSF1 in immune mechanisms of HCC, possibly related to HSF1 inducing PD-L1 expression in HCC; therefore addressing the issue will help to make a novel therapeutic strategy in HSF1 positive HCC patients. This evidence concerns the gene HSF1 and hepatocellular carcinoma.